Sorafenib as a second-line treatment after failure of atezolizumab-bevacizumab

被引：0
|
作者：
Tovoli, F. [1 ,2 ]
Boe, M. [1 ]
Vivaldi, C. [3 ]
Federico, P. [4 ]
Palloni, A. [5 ]
Dalbeni, A. [6 ,7 ,8 ]
Solda, C. [9 ]
Stefanini, B. [1 ]
Garajova, I. [10 ]
Ielasi, L. [11 ]
De Lorenzo, S. [12 ]
Granito, A. [1 ,2 ]
Stefanini, B. [1 ]
Masi, G. [3 ]
Lonardi, S. [4 ]
Brandi, G. [1 ,5 ]
Daniele, B. [4 ]
Auriemma, A. [7 ,13 ]
Lani, L. [1 ,14 ]
Svegliati-Baroni, G. [15 ]
Campani, C. [16 ]
Piscaglia, F. [1 ,2 ]
机构：
[1] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy
[2] IRCCS Azienda Osped Univ Bologna, Unit Internal Med Hepatobiliary & Immunoallerg Di, Bologna, Italy
[3] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
[4] Osped Mare, Med Oncol Unit, Naples, Italy
[5] IRCCS Azienda Osped Univ Bologna, Oncol Unit, Bologna, Italy
[6] Univ Verona, Dept Med, Unit Gen Med C, Verona, Italy
[7] Univ & Hosp Trust AOUI Verona, Verona, Italy
[8] Univ Verona, Liver Unit, Dept Med, Verona, Italy
[9] IRCCS, Veneto Inst Oncol IOV, Oncol Unit 1, Padua, Italy
[10] Univ Hosp Parma, Med Oncol Unit, Parma, Italy
[11] Osped Infermi Faenza, Dept Internal Med, Faenza, Italy
[12] Azienda USL Bologna, Oncol Unit, Bologna, Italy
[13] Univ Verona, Sect Innovat Biomed Oncol Area, Dept Engn Innovat Med DIMI, Verona, Italy
[14] IRCCS Azienda Osped Univ Bologna, Unit Semeiot Liver & Alcoholrelated Dis, Bologna, Italy
[15] Polytech Univ Marche, Liver Injury & Transplant Unit, Ancona, Italy
[16] Univ Firenze, Dipartimento Med Sperimentale & Clin, Florence, Italy
来源：
DIGESTIVE AND LIVER DISEASE | 2024年 / 56卷
关键词：
D O I：
10.1016/j.dld.2024.01.139
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
F-34
引用
收藏
页码：S79 / S79
页数：1
相关论文
共 50 条
  • [41] Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
    Cheon, J.
    Ryoo, B-Y.
    Kim, H-D.
    Kim, K-P.
    Ryu, M. H.
    Chon, H. J.
    Kang, B.
    Finn, R. S.
    Yoo, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1535 - S1536
  • [42] Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib
    Marotta, Vincenzo
    Di Somma, Carolina
    Rubino, Manila
    Sciammarella, Concetta
    Modica, Roberta
    Camera, Luigi
    Del Prete, Michela
    Marciello, Francesca
    Ramundo, Valeria
    Circelli, Luisa
    Buonomano, Pasqualina
    Colao, Annamaria
    Faggiano, Antongiulio
    ENDOCRINE, 2015, 49 (03) : 854 - 858
  • [43] Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib
    Vincenzo Marotta
    Carolina Di Somma
    Manila Rubino
    Concetta Sciammarella
    Roberta Modica
    Luigi Camera
    Michela Del Prete
    Francesca Marciello
    Valeria Ramundo
    Luisa Circelli
    Pasqualina Buonomano
    Annamaria Colao
    Antongiulio Faggiano
    Endocrine, 2015, 49 : 854 - 858
  • [44] Efficacy and Safety of Second-line Treatments in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: A Meta-analysis
    An, Limin
    Liao, Haotian
    Yuan, Kefei
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2021, 9 (06) : 868 - 877
  • [45] Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma
    Ochi, Hironori
    Kurosaki, Masayuki
    Joko, Kouji
    Mashiba, Toshie
    Tamaki, Nobuharu
    Tsuchiya, Kaoru
    Marusawa, Hiroyuki
    Tada, Toshifumi
    Nakamura, Shinichiro
    Narita, Ryoichi
    Uchida, Yasushi
    Akahane, Takehiro
    Kondo, Masahiko
    Mori, Nami
    Takaki, Shintaro
    Tsuji, Keiji
    Kusakabe, Atsunori
    Furuta, Koichiro
    Kobashi, Haruhiko
    Arai, Hirotaka
    Nonogi, Michiko
    Tamada, Takashi
    Hasebe, Chitomi
    Izumi, Namiki
    HEPATOLOGY RESEARCH, 2023, 53 (01) : 61 - 71
  • [46] Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
    Takada, Hitomi
    Kurosaki, Masayuki
    Tsuchiya, Kaoru
    Komiyama, Yasuyuki
    Itakura, Jun
    Takahashi, Yuka
    Nakanishi, Hiroyuki
    Yasui, Yutaka
    Tamaki, Nobuharu
    Maeyashiki, Chiaki
    Kaneko, Shun
    Takaura, Kenta
    Higuchi, Mayu
    Okada, Mao
    Wang, Wan
    Osawa, Leona
    Sekiguchi, Shuhei
    Hayakawa, Yuka
    Yamashita, Koji
    Enomoto, Nobuyuki
    Izumi, Namiki
    CANCERS, 2019, 11 (09)
  • [47] Bevacizumab plus temsirolimus as second-line treatment for advanced hepatocellular carcinoma (HCC)
    Chelis, Leonidas
    Deftereos, Savas
    Xenidis, Nikolaos
    Amarantidis, Kiriakos
    Hamalidou, Eleni Kyrillos
    Dimopoulos, Prokopios
    Michailidis, Prodromos
    Christakidis, Evagelos
    Mimidis, Kostantinos
    Pitsiava, Dimitra
    Karayiannakis, Anastasios
    Kakolyris, Stylianos
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Evaluation of safety of bevacizumab as second-line treatment of patients with metastatic colorectal cancer
    Todorovic, Vladimir
    Saric, Nada Cicmil
    Lakicevic, Jadranka
    Sorat, Milan
    JOURNAL OF BUON, 2017, 22 (05): : 1131 - 1136
  • [49] Second-Line Surgical Management After Midurethral Sling Failure
    Kwon, Joonbeom
    Kim, Yeonjoo
    Kim, Duk Yoon
    INTERNATIONAL NEUROUROLOGY JOURNAL, 2021, 25 (02) : 111 - 118
  • [50] Urothelial Carcinoma: Atezolizumab approved in the US as a Second-Line Therapy
    Dobler, Gabriele
    AKTUELLE UROLOGIE, 2019, 50 (01) : 16 - 16
12345